Country
Switzerland
The Roche group has staked out fibrotic disease as a growth area with the planned acquisition of Promedior Inc of Lexington, Massachusetts, US for up to $1.39 billion.
Full text available to subscribers only. Click here for information on subscribing to MedNous.